Skye Bioscience Inc
SKYE
Market Cap$107.7M
Close$
$1.86
54.7% downside
Current Fair Value
54.7% downsideOvervalued by 54.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $107.70 Million |
|---|---|
| Enterprise Value | $-44,187,655,035.00 |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-5.37 |
| Beta | 1.79 |
| Outstanding Shares | 38,669,330 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -3.25 |
|---|---|
| PEG | 0 |
| Price to Sales | - |
| Price to Book Ratio | 0.0 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 2075.73 |
| Enterprise Value to Net Income | 3 |
| Total Debt to Enterprise | -0.05 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Skye Bioscience Inc
11 employees
CEO: Brian Murphy nemus bioscience is a publicly traded, life-science biotech company, developing regulatory-approved, cannabinoid-based therapies, for a spectrum of diseases, especially those of unmet medical need.